Predictive Technology Group and Atrin Pharmaceuticals are collaborating to develop molecular diagnostic tools to improve selection of cancer patients who would most benefit from treatment with DNA Damage and Response inhibitors, including Atrin’s and other small molecule ATR inhibitors.
Kevan Shokat, a professor of cellular and molecular pharmacology at UC San Francisco, has won the second annual Stephenson Global Prize for research in pancreatic cancer.
